PUBMED FOR HANDHELDS

Journal Abstract Search


326 related items for PubMed ID: 22718450

  • 1. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P.
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [Abstract] [Full Text] [Related]

  • 2. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.
    Manrique J, Cravedi P.
    Nefrologia; 2014 May 21; 34(3):388-97. PubMed ID: 24798567
    [Abstract] [Full Text] [Related]

  • 3. [Monoclonal antibodies in nephrology: a delicate balance between curative potential, evidence of effectiveness, and toxicity].
    Magistroni R.
    G Ital Nefrol; 2012 May 21; 29(3):283-91; discussion 292. PubMed ID: 22718451
    [Abstract] [Full Text] [Related]

  • 4. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
    Ferrari P, Frey FJ.
    Ther Umsch; 1993 Feb 21; 50(2):119-29. PubMed ID: 8456416
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of post-transplant glomerulonephritis].
    Sandrini S, Valerio F.
    G Ital Nefrol; 2008 Feb 21; 25 Suppl 44():99-106. PubMed ID: 19048593
    [Abstract] [Full Text] [Related]

  • 6. [An innovative approach to the treatment of immune-mediated glomerular diseases].
    Roccatello D.
    G Ital Nefrol; 2013 Feb 21; 30(1):. PubMed ID: 23832439
    [Abstract] [Full Text] [Related]

  • 7. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar 21; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 8. Rituximab: emerging treatment strategies of immune-mediated glomerular disease.
    Kattah AG, Fervenza FC.
    Expert Rev Clin Immunol; 2012 Jul 21; 8(5):413-21. PubMed ID: 22882216
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic tests and treatment options in glomerular disease: 2014 update.
    Hogan J, Mohan P, Appel GB.
    Am J Kidney Dis; 2014 Apr 21; 63(4):656-66. PubMed ID: 24239051
    [Abstract] [Full Text] [Related]

  • 10. Drug insight: rituximab in renal disease and transplantation.
    Salama AD, Pusey CD.
    Nat Clin Pract Nephrol; 2006 Apr 21; 2(4):221-30. PubMed ID: 16932428
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine treatment of glomerular diseases.
    Klein M, Radhakrishnan J, Appel G.
    Annu Rev Med; 1999 Apr 21; 50():1-15. PubMed ID: 10073260
    [Abstract] [Full Text] [Related]

  • 12. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
    Kattah AG, Fervenza FC, Roccatello D.
    Autoimmun Rev; 2013 Jun 21; 12(8):854-9. PubMed ID: 23000633
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A, Bruchfeld A.
    Nephron Clin Pract; 2014 Jun 21; 128(3-4):277-82. PubMed ID: 25401966
    [Abstract] [Full Text] [Related]

  • 14. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY, Vogt B, Burnier M, Golshayan D.
    Rev Med Suisse; 2011 Apr 13; 7(290):819-24. PubMed ID: 21595313
    [Abstract] [Full Text] [Related]

  • 15. [The immunosuppressive therapy of chronic (Bright's) nephritis].
    Krasnova TN, Shilov EM.
    Ter Arkh; 1993 Apr 13; 65(6):88-93. PubMed ID: 8378860
    [No Abstract] [Full Text] [Related]

  • 16. New diagnostic tests and new therapies for glomerular diseases.
    Appel GB, Appel AS.
    Blood Purif; 2013 Apr 13; 35(1-3):81-5. PubMed ID: 23343551
    [Abstract] [Full Text] [Related]

  • 17. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
    AlSahow A, Al-Muhaiteeb A, Nawar H, AlHelal B, AlYousef A, Abdallah E, AbuShall A, Elmekawi S, Meshal B, AlQallaf A, AlRajab H.
    Med Princ Pract; 2022 Apr 13; 31(2):133-141. PubMed ID: 35021170
    [Abstract] [Full Text] [Related]

  • 18. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P, Remuzzi G, Ruggenenti P.
    Nephron Clin Pract; 2014 Apr 13; 128(3-4):261-9. PubMed ID: 25427622
    [Abstract] [Full Text] [Related]

  • 19. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.
    Autoimmun Rev; 2012 Jul 13; 11(9):646-52. PubMed ID: 22146313
    [Abstract] [Full Text] [Related]

  • 20. Use of mycophenolic acid in non-transplant renal diseases.
    Stassen PM, Kallenberg CG, Stegeman CA.
    Nephrol Dial Transplant; 2007 Apr 13; 22(4):1013-9. PubMed ID: 17307748
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.